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npv was 80.6%. Conclusion: For the first time, the VES-
13, G8, and POT are compared in a sample of older Ger-
man patients. The POT seems to be a sufficient screen-
ing tool to identify frail patients in a tertiary referral can-
cer center and helps to save time and resources com-
pared with a complete GA.
© 2016 S. Karger GmbH, Freiburg
Introduction
Cancer is the predominant cause of death in the elderly popula-
tion and presents health challenges as cancer rates continue to rise 
[1, 2]. In order to improve cancer care for older patients with a 
high risk of enhanced treatment-induced morbidity, international 
consensus guidelines and position papers on the use of a geriatric 
assessment (GA) have been created [3–5]. However, older patients 
are under-represented in clinical trials, resulting in difficulties with 
incorporating evidence-based clinical decision making for this het-
erogeneous group of patients [6]. As data are based on younger pa-
tients, survival estimates might have to be adjusted [7], making it 
more difficult to discuss the advantages and disadvantages of treat-
ment in elderly patients. Therefore, cancer therapy and decision 
making about treatment for older patients exhibit several difficul-
ties, especially, when considering general health status, comorbidi-
ties, polypharmacy, and functional and cognitive status. 
Keywords
Comorbidity · Frailty · Geriatric assessment · Screening · 
Toxicities
Summary
Background: The aim of this study was to identify an ap-
propriate screening instrument for the identification of 
frail elderly patients in a tertiary cancer center. In order 
to improve cancer care for older patients, the use of a 
geriatric assessment (GA) has been proposed to identify 
frail patients or those who are at a higher risk for chemo-
therapy-related toxicities. In busy clinical routine, an ap-
propriate screening instrument could be used to spare 
time- and resource-consuming application of GA. Pa-
tients and Methods: We administered the Vulnerable El-
ders Survey (VES-13), G8 questionnaire, and Predictors 
of Toxicity (POT) as well as a GA at the first visit of 84 
consecutive patients at a single Comprehensive Cancer 
Center. Analysis for patients’ characteristics as well as 
sensitivity, specificity, and positive and negative predic-
tive value (npv) was conducted. Results: The median age 
of the patients was 73 years (range 63–93 years), 61.9% 
were male, most (63%) suffered from gastrointestinal tu-
mors, 39.3% had a multiple cancer diagnosis, and 53.6% 
had metastasis. 30 (35.7%) individuals were classified as 
‘frail’ by the GA. Sensitivity of G8 was 38.3%, and the 
npv was 63.8%. Sensitivity for VES-13 was 57.1%, and 
npv was 76.3%. Sensitivity of POT was 72.7%, and the 
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Geriatric medicine uses the concept of frailty, despite the lack of 
an agreed upon definition [8, 9]. Hamaker et al. [9] summarize the 
characterization of frailty by Rockwood and Mitnitski [10] and 
Ferrucci et al. [8] as follows: ‘a state of decreased physiological re-
serves, arising from cumulative deficits in several physiological sys-
tems and resulting in diminished resistance to stressors’. This more 
holistic definition conflicts with the original definition by Fried et 
al. [11], which encompasses criteria such as weight loss, walk time, 
and kilocalories expanded during physical activity as well as cut-
offs for these measures. Thus, while Fried emphasizes more meas-
urable physiological aspects, Hamaker focuses on less specific and 
thereby also less measurable aspects to define frailty.
Despite the differences in defining frailty in terms of creating an 
effective assessment tool, conducting a geriatric assessment has 
proven to help predicting toxicity and morbidity [12, 13] and pro-
vides better information compared to the performance status 
judged by the physician [13, 14]. Some screening instruments have 
been developed to serve as an alternative to a time-consuming 
gold-standard GA, in order to identify patients at risk. Among oth-
ers, both the questionnaires G8 and the Vulnerable Elders Survey 
(VES-13) have been evaluated in routine oncologic practice [3, 15, 
16] and used in several studies [3, 9, 17, 18]. Heterogeneous report-
ing is found concerning the superiority of one instrument versus 
the other. While some data indicate no differences [9], others show 
that the sensitivity of the G8 is higher than that of the VES-13 and 
vice versa for specificity [18]; however, both the G8 and VES-13 are 
superior to most other screening measures [3].
Hurria et al. [19, 20] developed and evaluated the Predictors of 
Toxicity (POT), a primarily self-administered questionnaire de-
rived from geriatric domains to directly predict toxicity in elderly 
people undergoing chemotherapy. Similarly, both the G8 and the 
VES-13 have also been used to predict treatment-related toxicity 
[21]. Additionally, single domains from the GA have been identi-
fied to be of prognostic value for toxicities in elderly patients un-
dergoing chemotherapy [12, 22, 23].
Patients presenting at our tertiary cancer center are often diag-
nosed with advanced disease [24]. Stage at diagnosis depends on 
the respective entity, and the predominant tumor sites in this study 
were gastrointestinal, seldom diagnosed at a localized stage [25]. 
Besides predicting functional decline and overall survival [26, 27] 
as well as quality of life [28], one of the most important aims of a 
screening instrument in routine use is to predict toxicity from sys-
temic cancer treatment in an attempt to improve cancer care. 
Ultimately, even if VES-13 and G8 were developed to screen for 
frailty and POT was developed for predicting the different con-
struct of chemotherapy-related toxicities, all of the above tools aim 
to identify vulnerable patients. A comparison of the G8, VES-13, 
and POT is both necessary and interesting before implementing 
them in routine oncologic use in a tertiary referral cancer center, 
especially since no formal comparison of the most widely used in-
struments exists in older German patients.
Patients and Methods
Patients and Procedure
Patients were screened as part of their routine care at their first respective 
appointment for treatment of hematologic or oncologic diseases at the Compre-
hensive Cancer Center. As the applied questionnaires were part of routine ad-
mission procedure, all consecutive patients who consented to participate were 
eligible. This paper describes a subsample of patients older than 63 years. A GA 
and 3 geriatric screening instruments VES-13, G8, and POT were administered 
as part of the routine admission questionnaire on the patients’ first visit to the 
hospital. A printed form was handed out to the patients, and the questionnaire 
was self-administered. Additional information was derived from the patients’ 
files by medical documentarists. Patient data was obtained as part of the routine 
admission procedure, wherein patients consented to provide answers on the 
used questionnaires and to their data being processed and analyzed. No data of 
a sole individual is shown, all results are presented as merged data.
For the VES-13, complete data were obtained for analysis of psychometric 
parameters in 59 (70.2%) patients; for the G8, data could be used for 63 (75.0%) 
patients, and for the POT, 57 (67.9%) patients could be included. 39 (46.2%) 
patients completed all 3 instruments, 25 (29.8%) patients completed 2 instru-
ments, 12 (14.3%) patients completed 1 screening. 8 patients did not answer 
enough questions for calculation of any screening instrument.
All procedures performed in studies involving human participants were in 
accordance with the ethical standards of the institutional and/or national re-
search committee and the 1964 Helsinki declaration and its later amendments 
or comparable ethical standards. Ethical approval was obtained from the re-
sponsible ethics committee, and patients signed informed consent prior to 
study inclusion.
Geriatric Assessment
There is no consensus on the type, measurement, and cut-off of specific do-
mains to be included in a GA [29–31]. Most studies aiming to conduct a GA 
differ in the actual construct being measured [9]. The GA in this study included 
measures of 6 domains: cognition, psychological distress, instrumental activities 
of daily living (IADL), nutritional status, polypharmacy, and falls. These do-
mains were assessed as patient-reported outcomes based on well-established 
questionnaires and by manually searching the patients’ previous health records. 
Dimension Instrument Dimension impaired
Cognition search of electronic patient files file contains record of dementia
Psychological distress NCCN Distress Thermometer answer ≥ 5
IADL Instrumental Activities of Daily Living sum score < 8
Nutritional status Mini-Nutritional Assessment sum score ≤ 7
Polypharmacy single item: ‘Do you take more than 3  
different kinds of medication per day?’
‘yes’
Mobility/falls single item: ‘Did you fall during the last  
6 months’
‘yes’
Table 1. Overview of geriatric assessment (GA) 
and its measures
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Details on the measurements and scoring of each of these dimensions can be 
obtained from table 1. Previously published cut-off values for the identification 
of frail dimensions were used whenever available: the Distress Thermometer 
[32] for assessing psychological distress, the Short-Form Mini-Nutritional As-
sessment [33] for nutritional status, and the IADL of Lawton and Brody [34]. If 
no such score was available (polypharmacy, falls, diagnosis of cognitive impair-
ment such as dementia), a positive record in the patient’s file was set as identify-
ing a dimension as being frail. There is no consensus on how many dimensions 
of a GA should be impaired for classifying a patient as frail; studies use several 
different criteria [29–31]. Frailty was defined as 2 or more of the dimensions 
included in our GA being identified as ‘impaired’ [9], in order to specify a cut-
off value to prevent patients being casually classified as frail and to avoid ceiling 
effects. 
Screening Measures
Vulnerable Elders Survey – VES-13
Screening was conducted using the VES-13, a well-established and validated 
13-item screening tool, to identify the risk for death or functional decline in the 
geriatric population. This instrument was first tested in a sample of more than 
6,200 people aged 65 years or older with different diseases. Patients exceeding 
or equaling the cut-off of 3 points are at a 4.2 times higher risk of death or func-
tional decline in the next 2 years compared to those below the cut-off [35, 36]. 
We applied the same cut-off in our study.
Geriatric Screening Tool – G8
The G8 was introduced by Bellera et al. [16] in 2012 as a physician-assessed 
tool to identify geriatric cancer patients for whom the administration of a time-
consuming comprehensive GA would be beneficial. Patients can fill in this in-
strument with the assistance of a healthcare professional as described by 
Soubeyran et al. [18], even if the G8 was not developed as a self-administered 
tool. The G8 consists of 7 items based on the Mini-Nutritional Assessment [33] 
and a single item covering the patient’s age. This instrument was first tested in 
more than 360 cancer patients aged 70 years or older. Patients falling below the 
cut-off of 14 points are recommended to complete a GA [16]. This cut-off was 
also applied in our study. Currently, there are no studies reporting test-retest 
reliability or interrater reliability. Soubeyran et al. [18] reported a Cohen’s 
kappa of 0.65 between G8 and the respective items of a separately assessed 
Mini-Nutritional Assessment. 
Predictors of Toxicity – POT
The POT was used as a screening system for chemotherapy-related toxici-
ties. The POT consists of different items and parameters covering geriatric con-
ditions (i.e., falls, liver or kidney disease), laboratory values (i.e., albumin, 
hemoglobin), activities of daily living, and tumor-related information (i.e., dos-
age of chemotherapy, type of cancer). Answers were provided by healthcare 
professionals using both laboratory data and patient files. This instrument was 
first tested in 500 tumor patients. According to the patients’ scores, ranging 
from 0 (indicating low risk) to 23 (indicating high risk), patients are classified 
into groups indicating low (0–5 points), intermediate (6–9 points), or severe 
risk (10–23 points) for side effects [20]. In this study, every patient with a score 
equal to or above 9 points was considered frail.
Furthermore, the performance status developed by the Eastern Cooperative 
Oncology Group (ECOG) was assessed [37]. This measure describes a patient’s 
level of functioning, i.e., caring for him-/herself, physical ability, and daily ac-
tivity. It ranges from 0 (‘fully active’) to 5 (‘dead’) and is assessed by a healthcare 
professional. 
Statistical Analysis
We conducted analyses for sensitivity, specificity, positive and negative pre-
dictive value of the screening-tools and our GA, as well as their respective 95% 
confidence intervals (CI) by using Excel 2010 (Microsoft, Redmond, WA, USA) 
and SPSS 22 (IBM Corp., Armonk, NY, USA) [38]. Sensitivity measures the 
number of patients with a positive screening among all frail patients. Specificity 
measures the number of patients with a negative screening among all healthy 
patients. Positive predictive outcome describes the number of frail patients 
among all patients screened positive. Negative predictive outcome describes the 
number of healthy patients among all patients screened negative. 
Furthermore, we used for each screening tool separate receiver operating 
characteristic (ROC) curves to analyze the diagnostic performance of all 3 
screening tools against the GA. The area under the curve (AUC) was calculated 
as a measure of overall predictive quality of the respective instrument. 
Results
Sample Description
A total of 84 consecutive geriatric patients of a German cancer 
center were included from 04/2013 to 06/2013 in this cross-sec-
tional cohort study. For this sample, ‘geriatric’ was defined as being 
63 years of age or older. Patient characteristics are summarized in 
table 2. The median age of the study patients was 73 years (range 
63–93 years). 61.9% were male. Almost 40% had a multiple cancer 
diagnosis, and more than 50% had metastatic disease.
Table 2. Patient characteristics
Characteristics
Median age (range), years 73 (63–93)
Patients, n (%)
Sex
Female 32 (38.1)
Male 52 (61.9)
ECOG score
0 24 (28.6)
1 22 (26.1)
2  3 (3.6)
3  2 (2.4)
4  0 (0.0)
Not available 33 (39.3)
Multiple cancer diagnosis
Yes 33 (39.3)
No 51 (60.7)
Patients with metastases
Yes 45 (53.6)
No 39 (46.4)
Cancer type (n = 125 ICD diagnosesa)
Gastrointestinal 64 (51.2)
Mesothelial and soft tissue  6 (4.8)
Male genital organs  4 (3.2)
Malignant neoplasm of the breast  6 (4.8)
Malignant neoplasms, primary, of lymphoid,  
hematopoietic, and related tissues
 3 (2.4)
Melanoma and other skin 11 (8.8)
Neoplasms of uncertain or unknown behavior  7 (5.6)
Respiratory and intrathoracic organs  7 (5.6)
Urinary tract  8 (6.4)
Other  9 (7.2)
aMultiple diagnoses per patient were counted separately.
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Frail Patients
Frailty was defined as equaling or exceeding 2 ‘impaired’ di-
mensions. Out of 84 patients, 30 (35.7%) individuals were classified 
as ‘frail’ by the GA. Among those, a complete GA was available in 
21 patients. In non-frail patients, a full GA was available in 16 indi-
viduals. 22 persons had 2 impaired dimensions, 7 individuals held 
3 impaired dimensions, and 1 patient held 4 impaired dimensions. 
At least 5 out of 6 dimensions of the GA were available for 65 
(77.4%) patients. Of all the patients classified as frail, 13 (43.3%) 
were male and 17 (56.7%) female. Overall, female patients seemed 
to have more impaired dimensions (mean 1.5) than their male 
counterparts (mean 1.1; t(54) = 2.01) (p < 0.05). Details on which 
dimensions were impaired can be obtained from table 3. The mean 
age of the patients classified as frail was 72.2 years, whereas pa-
tients not classified as frail were on average 73.4 years old, a differ-
ence that failed to reach statistical significance (t(82) = 1.08; p = 
0.370). The ECOG performance status was obtained in 51 patients 
(20 frail and 31 non-frail) and was ECOG = 0 in 24 patients, ECOG 
= 1 in 22 patients, ECOG = 2 in 3 patients, and ECOG = 3 in 2 pa-
tients. Patients classified as frail received a higher averaged ECOG 
status (= 0.850) than the non-frail group (= 0.548), a difference that 
failed to reach statistical significance (t(49) = 1.72; p = 0.172). 
Predictive Value of Screening Instruments
The 3 geriatric screening instruments were assessed for their 
sensitivity, specificity, positive predictive value, and negative pre-
dictive value for identifying patients as ‘frail’ using a GA. 
As seen in table 4, the sensitivity of VES-13 was 57.1% (95% CI 
44.5–69.8%), specificity was 79.2% (95% CI 44.5–69.8%), the posi-
tive predictive value was 62.1% (95% CI 48.7–73.6%), and the neg-
ative predictive value was 76.3% (95% CI 65.4–87.1) based on the 
analysis of 59 patients. Out of these, 35 (59.3%) patients exceeded 
the cut-off. The mean VES-13 score was 5.4 (standard deviation 
(SD) 2.7) for patients being classified as frail by the GA, whereas 
patients that were being classified as non-frail had a mean score of 
3.1 (SD 2.6), a difference that was highly significant (p = 0.002).
As demonstrated in table 4, the sensitivity of the G8 was 38.3% 
(95% CI 25.9–50.7%), specificity was 62.5% (95% CI 50.1–74.9%), 
the positive predictive value was 37.0% (95% CI 24.6–49.3%), and 
the negative predictive value was 63.8% (95% CI 51.6–76.1%) based 
on the analysis of 63 patients. Of these, 47 (74.6%) patients scored 
below the cut-off. The mean G8 score was 11.9 (SD 2.4) for pa-
tients being classified as frail by the GA. Persons being classified as 
non-frail had a mean score of 13.3 (SD 2.0), a difference that was 
highly significant (p = 0.025). 
As shown in table 4, the sensitivity of POT was 72.7% (95% CI 
61.2–84.3%), specificity was 65.2% (95% CI 52.9–77.6%), the posi-
tive predictive value was 54.6% (95% CI 41.6–67.5%), and the neg-
ative predictive value was 80.6% (95% CI 70.4–90.9%) based on the 
analysis of 57 patients. Of these, 11 (19.3%) patients exceeded the 
cut-off. The mean POT score was 10.8 (SD 3.2) for patients being 
classified as frail by the GA, whereas patients classified as non-frail 
had a mean score of 8.4 (SD 2.7), a difference that was highly sig-
nificant (p = 0.004).
Compared Predictive Performance
The ROC curves of the VES-13 (AUC = 0.733), the G8 (AUC = 
0.350), and the POT (AUC = 0.725) are presented in figure 1 a–c. 
Patients with impaired dimension (assessable  patients)
Domain overall female male 
Cognition  2 (83)  1 (32)  1 (51)
Psychological distress 48 (70) 20 (26) 28 (44)
Instrumental activities of daily living 23 (47) 13 (25) 10 (22)
Nutritional status  1 (63)  1 (27)  0 (36)
Polypharmacy 29 (84) 13 (32) 16 (52)
Falls  4 (84)  1 (32)  3 (52)
Patients with CGA classification, n (% of total)
overall female male
Classification as ‘frail’ by geriatric assessment 30 17 (20.2) 13 (15.5)
Classification as non-frail by geriatric assessment 54 15 (17.9) 39 (46.4)
Mean count of impaired dimensions  1.5  1.1
Table 3. Prevalence 
of geriatric impaired 
dimensions
VES-13 (n = 59),
% (95% CI)
G8 (n = 63),
% (95% CI)
POT (n = 57),
% (95% CI)
Sensitivity 57.1 (44.5–69.8%) 38.3 (25.9–50.7%) 72.7 (61.2–84.3%)
Specificity 79.2 (68.8–89.5%) 62.5 (50.1–74.9%) 65.2 (52.9–77.6%)
Positive predictive value 61.2 (48.7–73.6%) 37.0 (24.6–49.3%) 54.6 (41.6–67.5%)
Negative predictive value 76.3 (65.4–87.1%) 63.8 (51.6–76.1%) 80.6 (70.4–90.9%)
Table 4. Diagnostic 
parameters of the Vul-
nerable Elders Survey 
(VES-13), G8 question-
naire, and Predictors of 
Toxicity (POT)
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Discussion
To our knowledge, this study is the first to compare the predic-
tive qualities of G8, VES-13, and POT in a prospective trial in a 
sample of elderly cancer patients in Germany. Our study reports 
on a patient group referred to a tertiary cancer center. Therefore, 
the results provide useful information applicable to everyday situa-
tions in a tertiary cancer center when trying to evaluate the predic-
tive characteristics of these geriatric screening instruments and 
their feasibility in oncology practice.
Compared with a full GA and the other screening tools, the G8 
shows limited predictive qualities. Ultimately, the predictive quality 
of the G8 in our study was below that reported by others (sensitivity 
of 92% [31] and 85% [16]). When comparing those results, we 
found some differences regarding the study population. First, the 
percentage of patients with an abnormal screening score presented 
in the other studies was much higher (76–82%) as compared to our 
study population (36%). In a further step, we looked in more detail 
at the different cut-off values for G8 used in other studies. Bellera et 
al. [16] proposed a value of  14 as the preferred cut-off for identifi-
cation of elderly frail patients as we did in our study. In contrast, 
Baitar et al. [31] used a different approach and calculated the pre-
dictive parameters for different cut-offs of G8. Applying the same 
procedure for explorative reasons, an alternative G8 cut-off of  11 
produces the best sensitivity of 73% and a specificity of 73%. A third 
difference concerns the age of the study populations: The median 
age of the population of Bellera et al. [16] was 77 years, whereas the 
median age in our group was 73 years. Patients with gastrointestinal 
cancer comprised 38% in that study, while our study indicated a 
higher rate of 51.2%. Another substantial difference was the rate of 
hematologic patients (30%) compared to our study (2%). Moreover, 
the G8 predominately relies on malnutrition, which might limit the 
predictive quality for patients that are compromised in that way 
while others could be overlooked. In conclusion, the differences in 
accuracy could be ascribed to the fact that our patient population 
does not compare well with the others. Since tumor location and 
histology can impact the ability to detect patients at risk [21, 39], a 
more detailed definition of the target population might be needed 
in order to achieve maximum accuracy. 
The VES-13 shows moderate sensitivity and a moderate positive 
predictive outcome, as well as good specificity and negative predic-
tive outcome. Interestingly, the accuracy for the VES-13 was very 
comparable to the data reported by others [17, 18, 29, 40]. The 
AUC of the VES-13 was bigger than that of the G8 and comparable 
to the AUC found by Luciani et al. [15], but smaller than that 
found by Mohile et al. [41]. When comparing these 2 screening in-
struments for frailty, the VES-13 is more sensitive than the G8 in 
identifying frail patients. Although the sensitivity is not as high as 
the minimal acceptable sensitivity of 85% predefined by Smets et 
al. [42], it is well in line with the results of several studies reviewed 
by Decoster et al. [3]. For identifying patients not in need of a fur-
ther assessment based on a GA, the VES-13 is also more specific 
than the G8. These findings are in contrast to those reported by 
Soubeyran et al. [18] who observed a superiority of the G8 regard-
ing sensitivity. For typical patients of a tertiary cancer center, the 
VES-13 seems to be a sufficient screening tool to identify frail pa-
tients; however, it is still only slightly better than identifying pa-
tients by chance. More importantly, the combination of both in-
struments (VES-13 and G8), as tested by others [40, 43], did not 
show superior results in our group (data not shown).
The POT, which was developed and introduced much more re-
cently, shows a high sensitivity and moderate positive predictive 
outcome as well as good specificity and a high negative predictive 
value. Therefore, the POT seems to be a promising instrument not 
Fig. 1. Receiver oper-
ating characteristic 
analysis of a the Vul-
nerable Elders Survey 
(VES-13), b G8 ques-
tionnaire, and c Pre-
dictors of Toxicity 
(POT) (straight black 
line = area under the 
curve; dashed line = 
reference line of ‘no 
discrimination’).
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only in predicting chemotherapy-associated toxicities but also in 
detecting patients in geriatric oncology that are at risk in general. 
This would be another reason to choose the POT over other 
screening instruments since it can be used to predict toxicity fur-
ther on in the course of treatment. 
We also observed a difference in ECOG status in patients classi-
fied as frail by the GA. These patients have a worse ECOG status 
than those classified as non-frail. This effect failed to reach signifi-
cance, which is strikingly interesting, as ECOG performance status 
is frequently used as a criterion for chemotherapy dosage [14] and 
for frailty screening [44]. Additionally, Wildes et al. [45] found that 
ECOG is not significantly associated with grade III or IV toxicities 
or mortality prediction. Therefore, besides other relevant factors 
for dosage of chemotherapy, a GA or an appropriate screening 
could contribute to decision making about the dosage of chemo-
therapy in frail patients beyond the ECOG.
Furthermore, our data indicated an unexpected finding. There 
was a non-significant difference between the age of frail (72.2 
years) and non-frail (73.4 years) patients. The non-frail group was 
older than those classified as frail, indicating that in clinical rou-
tine, age should definitely not be used as an ‘ultra-short’ and easy-
to-administer screening for frailty. 
This study also has some limitations. Since it was carried out in 
the framework of the daily routine admission procedure at a ter-
tiary cancer center and not as a predefined study, the GA could not 
solely use methodologically elaborated questionnaires due to both 
time and resource constraints. For example, we measured mobility 
with a single-item question instead of using standardized methods 
such as the Timed Up & Go test [46] or the ‘Ten-meter Timed 
Walk Test’ [47], and cognition was assessed by manual search of 
electronic patient files in our tumor documentation system instead 
of applying a more elaborate instrument such as those described by 
Lange et al. [48]. Ultimately, no consensus on 1 definitive GA ex-
ists, and therefore most studies differ in what exactly is being meas-
ured [9]. Thus, our study adds to the variety of different ap-
proaches of measuring the GA domains. Using single-item ques-
tions could contribute to sparing time and resources. The authors 
are aware that the rate of missing data is a further limitation. As 
this study was carried out in the framework of routine admission 
procedures, immediate examination of the data completion rate 
was not always possible. Furthermore, time could have been lim-
ited by clinical routine, e.g. patients may have had to stop filling in 
the questionnaires in order to meet their appointment with a treat-
ing physician. Additionally, the low number of patients completing 
all 3 screening instruments limits their comparability. Further tri-
als should focus on this as well as on data integrity by e.g. using 
electronical devices which were proven to be usable for data collec-
tion even in routine care [49–51].
Conclusion
In the search for an appropriate screening tool to identify vul-
nerable elderly patients without administering a complete GA, the 
data from our tertiary cancer center have indicated that the POT is 
the best available tool providing sufficient sensitivity and a high 
negative predictive value. Since single-item questions can already 
provide substantial knowledge in a risk assessment [52], it is a chal-
lenging and important task for future research to identify easy and 
quick to perform instruments in selected patient populations to de-
tect frailty and potential harm of therapy.
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